WeVote
Log In

Bill

Bill

HB 2817

Creates provisions relating to ibogaine treatment

2026 Regular Session Introduced by Matthew Overcast

Missouri would fund FDA-supervised ibogaine trials for veterans’ opioid and mental health issues through dedicated grants and two non-reverting funds, with strict oversight.

Placed Back on Formal Perfection Calendar (H)
#mentalhealth #veterans
0
WeVote Research Nonpartisan
Bill Summary · HB 2817

Summary of HB 2817 (2026) – Missouri: Veterans Mental Health Innovation Act

Overview
- Purpose: Establish a structured, FDA-supervised framework to fund and conduct ibogaine clinical drug development trials for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions, with a specific focus on veterans.
- Jurisdiction: Missouri
- Key mechanism: Creation of dedicated funds and grant programs administered by the Department of Health and Senior Services (DHSS), supported by non-reverting state funds and private contributions.

Main Goals and Intent
- Bring FDA-overseen ibogaine research and clinical trials to Missouri institutions.
- Target illnesses that disproportionately affect veterans, including opioid use disorder, PTSD-related conditions, and other mental health challenges.
- Create dedicated funding streams to support research, while ensuring safety, accountability, and transparency through reporting requirements.

Substantive Provisions and Changes
- Authorization of Grants (Section 191.1616)
- The DHSS may award grants (subject to appropriation) to conduct certified FDA-supervised clinical drug development trials on ibogaine and its analogs.
- Eligible applicants must be located in Missouri and meet several criteria related to neurological research, neurosurgery capacity, research capability, and commitment to matching funds from non-state sources.
- Applicants must have an agreement with a multistate consortium established by another state government that:
- Has submitted an IND to FDA (21 CFR Part 312).
- Has requested FDA Breakthrough Therapy designation for ibogaine (21 U.S.C. § 356).

  • Funding and Governance

    • Establishment of the "Ibogaine Study Fund" in the state treasury to finance these grants.
    • Fund is dedicated and non-reverting; eligible funds include General Assembly appropriations and gifts/grants/bequests from federal/private sources.
    • State Treasurer administers disbursements consistent with §§ 30.170 and 30.180.
    • The department must verify that state funding includes matching funds from non-state sources before disbursement.

  • Intellectual Property and Revenue (Section 191.1622)

    • Creation of the "Ibogaine Intellectual Property Fund" to hold revenues and rights arising from ibogaine trials and later commercialization.
    • Fund is dedicated and used solely for programs assisting veterans or other at-risk populations in Missouri.
    • Includes a broad definition of intellectual property and related rights (inventions, patents, trade secrets, data, treatment models, etc.).

  • Clinical Practice and Oversight (Section 191.1625)

    • If ibogaine is FDA-approved for a medical condition, prescribing is limited to physicians licensed under Missouri law.
    • Supervising physician must oversee administration of ibogaine in a licensed hospital or health facility to ensure patient safety during administration.

  • Reporting and Accountability (Section 191.1619)

    • Quarterly progress and financial status reports from grant recipients to the DHSS.
    • Annual progress and financial status report to the Missouri General Assembly by December 1 each year.

  • Miscellaneous Implementation Notes

    • DHSS may start accepting grant applications before November 1, 2026.
    • The bill contemplates federal waivers or authorizations as needed for implementation, with potential delays if waivers are required.

Estimated Fiscal Impact (per legislative fiscal note)
- General Revenue impact: Net positive, with potential gains in revenue through appropriations to the Ibogaine Study Fund and related matching funds. Projected net effect ranges across years show substantial potential increasing general revenue if the program is funded at stated levels.
- Grant costs: Estimated to be $6–8 million for Phase I (FY27), $15–25 million for Phase II (FY28–29), and $60–180 million for later phases (FY30+), subject to appropriations and the number of trials.
- Staffing: About 5 FTEs in DHSS to administer the program.
- Funds: Creation of two dedicated funds (Ibogaine Study Fund and Ibogaine Intellectual Property Fund); funds are non-reverting and dedicated to their respective purposes.

Audience and Affected Parties
- Primary: Missouri veterans and veterans' service organizations (with a focus on mental health and substance use conditions).
- Research institutions in Missouri, particularly those with neurosurgery and clinical trial capabilities.
- Physicians and hospitals licensed in Missouri.
- Private partners and consortia engaged in FDA-regulated ibogaine research.

Timeline Highlights
- Grant applications to begin before November 1, 2026.
- Ongoing quarterly and annual reporting requirements to the DHSS and General Assembly.
- Potential Phase I start in FY2027, Phase II in FY2028–FY2029, with Phase III contingent on FDA progression (not expected until 2030+).

Notes and Considerations
- The program links Missouri funding to externally governed, out-of-state consortia and FDA processes, introducing governance and compliance risk if partnering entities or IND status change.
- The proposal emphasizes veteran-focused outcomes and a regulated research pathway rather than broad legalization or recreational use.
- Several stakeholders (e.g., Missouri State Medical Association) have raised concerns about safety, liability, and regulatory dependencies.

This summary captures the bill’s core structure, funding architecture, and its intended impact on veteran mental health research through FDA-approved ibogaine trials.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.